In the randomized Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (intent to treat: 1,961 adults with overweight or obesity without T2D), once-weekly subcutaneous semaglutide 2.4 mg resulted in greater weight loss compared with placebo over a 68-week period (estimated treatment difference 12.4 percentage points, 95% confidence interval (CI) 13.4, 11.5
Some plans cover it, some require prior authorization, and some deny it entirely for non-diabetic patients
1 Its incidence has steadily increased across all age groups over the past few years, contributing significantly to the global healthcare burden
In the end, finding the right balance with GLP-1 medications needs careful thought and personal advice from doctors
PlexusDx clinicians monitor these patterns through weekly check-ins during titration and have authority to pause or reduce dosing based on your reported tolerance and weight loss progress
No matter what a fad diet or product may promise, the fact is that weight loss comes with burning more calories than you take in, so diet and exercise are the main keys to success if you want to lose weight